# KLOW Peptide Dosage Research: Composition, Half-Lives and Research Context > KLOW peptide dosage research context — the canonical 80 mg vial composition, individual component half-lives, routes studied, and the pharmacokinetic mismatch that defines the blend. Research use only. No human dose for the blend exists. No validated human dosing exists for any component in this formulation. What follows is the research context: what was administered to which species, at what dose, by what route. ## In plain words KLOW peptide is a research-only blend. There is no human clinical trial, no FDA-approved dosing schedule, and no validated protocol for the four-peptide combination. What this page covers is the canonical vial composition used in research settings, the dose ranges each component has been studied at in rodents and cells, and the key pharmacokinetic (the science of how fast a substance enters, moves through and leaves the body) facts that make this a structurally unusual blend. Specifically, the four compounds clear the body at very different rates — a mismatch that is inherent in a co-formulated vial and that no research team has formally characterized for this mixture. No doses here are human recommendations. ## KLOW blend The canonical KLOW research vial contains 80 mg total across four components: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. GHK-Cu is the mass-dominant arm at ~62.5% of the vial by mass. The blend is supplied lyophilized (freeze-dried) and reconstituted with bacteriostatic water for laboratory handling. A theoretical stability note: copper(II) in GHK-Cu can participate in redox chemistry (oxidation-reduction reactions involving electron transfer). Co-dissolving it with three other peptides in one vial raises a question about compatibility and oxidation that has not been formally characterized for this mixture. This is a structural chemistry consideration, not an established safety finding. ## KLOW peptide dosage No validated human dosing exists for the KLOW blend. Component-level research doses differ widely by species, route and study design and are not additive into a single 'KLOW dose': **GHK-Cu (50 mg / ~62.5% of vial).** In vitro: collagen synthesis was stimulated at 10⁻¹² to 10⁻⁹ M in human fibroblast cultures [8]. Topical human trials for hair growth used a GHK-containing complex at 50 and 100 mg/mL applied to the scalp [11]. Topical: skin-penetration research measured permeation across ex-vivo human dermatomed skin — 136.2 ± 17.5 μg/cm² over 48 hours with 97 ± 6.6 μg/cm² retained as a dermal depot [10]. GHK-Cu has the most developed human-topical data of the four components. **KPV (10 mg / 12.5% of vial).** In vitro at 10 nM in human intestinal epithelial cells; oral at 100 μM in drinking water in DSS/TNBS colitis mice [3]. PepT1 Km ~160 μM (the concentration at which the transporter operates at half its maximum speed). Human data are restricted to delivery pilots and the historical IBD-program lineage. **BPC-157 (10 mg / 12.5% of vial).** Rat studies used 10 μg, 10 ng, or 10 pg per rat by intraperitoneal injection once daily [2]. The one human safety pilot administered 10 mg IV on day 1 and 20 mg IV on day 2 in 250 cc saline over 1 hour in two healthy adults [6]. No efficacy dose has been established in humans. **TB-500 (10 mg / 12.5% of vial).** Most cited data are for full-length thymosin beta-4, not the TB-500 fragment. Rat wound studies used topical and IP routes; as little as 10 pg of Tbeta4 stimulated keratinocyte migration 2-3-fold in vitro [1]. Clinical-grade RGN-259 ophthalmic formulation used 0.1% solution [12]. ## KLOW dosage The pharmacokinetic profile of the KLOW blend as a whole has never been characterized. The four components have markedly different reported half-lives, creating a structural mismatch within a single co-formulated vial: KPV and GHK-Cu are small tripeptides (MW 342 and 403 Da respectively) and are expected to clear from plasma rapidly — minutes to low single-digit hours in standard models for peptides of this size. BPC-157 (MW 1419 Da) has a short but formally longer elimination half-life; in the only published pharmacokinetic context it was described as short in rat plasma. TB-500 (MW 889 Da, the heptapeptide fragment) has no published formal PK characterization as a separate compound. The consequence: a single co-dissolved dose of all four cannot hold all components at matched plasma exposures. The tripeptides will have largely cleared before BPC-157 and TB-500 have reached any tissue target. This is a structural limitation of the co-formulation design, not a safety finding — but it is the central reason all 'synergy' claims are mechanistic extrapolation rather than observed blend data. ## KLOW peptide dosage and frequency Research protocols for each component vary widely in dose frequency. Thymosin beta-4 studies in rats used once-daily topical or IP administration over 7-day wound-closure windows [1]. BPC-157 rat tendon studies used once-daily IP injection [2]. KPV colitis studies used continuous oral administration via drinking water [3]. GHK-Cu topical hair-growth trials ran for 6 months with regular scalp application [11]. None of these schedules apply to the blend. A co-formulated vial changes the dosing calculation for every component simultaneously, and the pharmacokinetic mismatch (described above) means no single frequency can hold all four components in any particular exposure window. Research on individual component frequency does not transfer to KLOW frequency. No human protocol for the blend exists. ## Routes studied in the component literature Each KLOW component has been studied by one or more routes: - **Subcutaneous injection** — the primary route in research-use handling for peptide blends. - **Intraperitoneal injection** — used in most rodent studies for BPC-157 and thymosin beta-4/TB-500. - **Topical** — GHK-Cu has the most developed topical data (cosmetic, skin-penetration, hair-growth trials); RGN-259 (Tbeta4 ophthalmic) is a clinical-grade topical. - **Oral / targeted delivery** — KPV and BPC-157 have been studied in oral and colon-targeted nanoparticle delivery models in mice [3, 14]. - **Intravenous infusion** — the 2025 BPC-157 safety pilot used IV infusion [6]. Route matters for each component differently. GHK-Cu's topical permeation data is specific to dermal delivery; oral KPV relies on PepT1-mediated uptake in inflamed gut epithelium. These route-specific mechanisms do not generalize across delivery methods. --- A fog-lit reading room: four component literatures set down as four separate currents, each cited to its own study, the absent blend experiment kept openly dark.